Phase 1 final results and phase 2a dose selection for cerdulatinib (Prt062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies Meeting Abstract

   


Authors: Hamlin, P.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; Kim, Y.; Curnutte, J.; Patel, M.
Abstract Title: Phase 1 final results and phase 2a dose selection for cerdulatinib (Prt062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies
Meeting Title: 21st Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 101
Issue: Suppl. 1
Meeting Dates: 2016 Jun 9-12
Meeting Location: Copenhagen, Denmark
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2016-06-01
Start Page: 446
Language: English
ACCESSION: WOS:000379484601460
PROVIDER: wos
PMCID: PMC4894295
Notes: Meeting Abstract: LB2252 -- Source: Wos